Invesco Pharmaceuticals ETF (NYSEARCA:PJP) Short Interest Update

Invesco Pharmaceuticals ETF (NYSEARCA:PJP) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 40,386 shares, an increase of 481.9% from the December 31st total of 6,940 shares. Based on an average daily volume of 141,970 shares, the short-interest ratio is presently 0.3 days. Approximately 1.1% of the company’s shares are sold short. Approximately 1.1% of the company’s shares are sold short. Based on an average daily volume of 141,970 shares, the short-interest ratio is presently 0.3 days.

Invesco Pharmaceuticals ETF Price Performance

NYSEARCA PJP opened at $106.11 on Wednesday. The firm has a market capitalization of $398.97 million, a price-to-earnings ratio of 15.59 and a beta of 0.50. The company has a 50 day simple moving average of $105.48 and a 200-day simple moving average of $96.39. Invesco Pharmaceuticals ETF has a 52-week low of $72.25 and a 52-week high of $108.40.

Institutional Investors Weigh In On Invesco Pharmaceuticals ETF

A number of hedge funds and other institutional investors have recently made changes to their positions in PJP. Trilogy Capital Inc. acquired a new position in Invesco Pharmaceuticals ETF in the second quarter worth about $1,330,000. BNP Paribas Financial Markets acquired a new stake in shares of Invesco Pharmaceuticals ETF in the 2nd quarter valued at $799,000. Ameriprise Financial Inc. grew its holdings in shares of Invesco Pharmaceuticals ETF by 214.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 12,236 shares of the company’s stock worth $1,114,000 after purchasing an additional 8,344 shares during the last quarter. Citadel Advisors LLC acquired a new stake in shares of Invesco Pharmaceuticals ETF during the 3rd quarter worth about $504,000. Finally, WBI Investments LLC acquired a new position in Invesco Pharmaceuticals ETF in the third quarter valued at about $499,000.

About Invesco Pharmaceuticals ETF

PowerShares Dynamic Pharmaceuticals Portfolio (the Fund) is a non-diversified fund. The Fund seeks investment results that correspond generally to the price and yield of the Dynamic Pharmaceuticals Intellidex Index (the Index). The Index evaluates companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. The Index consists of stocks of 30 United States pharmaceutical companies. These are companies that are principally engaged in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types.